We Are Crinetics
Crinetics is a pharmaceutical company that develops much-needed therapies for people with rare endocrine diseases. We’re here for patients who are eager to find therapies that provide effective disease control and more simplicity in their lives. We partner with healthcare practitioners to ensure we’re solving real problems for them. And we build value in the company for investors by filling real market needs. Whatever brought you here, welcome.
Read the Latest
March 10, 2023
Crinetics Announces March 2023 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics Pharmaceuticals announces March 2023 inducement grants: the stock options were granted as inducements material to eight employees entering into employment with Crinetics in accordance with Nasdaq Listing Rule 5635(c)(4).
February 28, 2023
Crinetics Reports Fourth Quarter and Full Year 2022 Financial Results
Crinetics Pharmaceuticals reported financial results for the fourth quarter and year ended December 31, 2022
Pipeline
We support patients, endocrinologists, and healthcare providers by finding better therapies for rare endocrine diseases and endocrine oncology such as:
- Acromegaly
- Neuroendocrine tumors (NETs)
- Carcinoid syndrome
- Congenital hyperinsulinism (congenital HI)
- Syndromic hyperinsulinism (syndromic HI)
- Cushing’s disease
- Congenital adrenal hyperplasia (CAH)
- Hypercalcemia
Our once-daily, oral, investigational drug for the treatment of acromegaly is in Phase 3. But that’s just at the forefront of the important work we’re doing to combat endocrine disease.
Discovery | Pre-Clinical | Phase 1 | Phase 2 | Phase 3 |
---|---|---|---|---|
Acromegaly (PATHFNDR-1, 2)
Discovery | Pre-Clinical | Phase 1 | Phase 2 | Phase 3 |
---|---|---|---|---|
Acromegaly (PATHFNDR-1, 2)